JP2018536393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536393A5
JP2018536393A5 JP2018518451A JP2018518451A JP2018536393A5 JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5 JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5
Authority
JP
Japan
Prior art keywords
seq
region
antibody
fragment
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018518451A
Other languages
English (en)
Japanese (ja)
Other versions
JP6862435B2 (ja
JP2018536393A (ja
Filing date
Publication date
Priority claimed from GBGB1517913.8A external-priority patent/GB201517913D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073587 external-priority patent/WO2017060201A1/en
Publication of JP2018536393A publication Critical patent/JP2018536393A/ja
Publication of JP2018536393A5 publication Critical patent/JP2018536393A5/ja
Application granted granted Critical
Publication of JP6862435B2 publication Critical patent/JP6862435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018518451A 2015-10-09 2016-10-04 抗wt1/hla特異的抗体 Expired - Fee Related JP6862435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239438P 2015-10-09 2015-10-09
GBGB1517913.8A GB201517913D0 (en) 2015-10-09 2015-10-09 Anti-WT1/HLA-specific antibodies
US62/239,438 2015-10-09
GB1517913.8 2015-10-09
EP15189753.5 2015-10-14
EP15189753 2015-10-14
PCT/EP2016/073587 WO2017060201A1 (en) 2015-10-09 2016-10-04 Anti-wt1/hla-specific antibodies

Publications (3)

Publication Number Publication Date
JP2018536393A JP2018536393A (ja) 2018-12-13
JP2018536393A5 true JP2018536393A5 (enExample) 2019-11-14
JP6862435B2 JP6862435B2 (ja) 2021-04-21

Family

ID=58487775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518451A Expired - Fee Related JP6862435B2 (ja) 2015-10-09 2016-10-04 抗wt1/hla特異的抗体

Country Status (6)

Country Link
US (2) US10836829B2 (enExample)
EP (1) EP3359565A1 (enExample)
JP (1) JP6862435B2 (enExample)
HK (1) HK1258444A1 (enExample)
MA (1) MA45004A (enExample)
WO (1) WO2017060201A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
EP3366704A1 (en) * 2017-02-28 2018-08-29 Affimed GmbH Antibodies specific for mmp1/hla-a2 complex
EP3630846A4 (en) * 2017-05-31 2021-02-24 Carsgen Therapeutics Co., Ltd. COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY
CR20200014A (es) 2017-07-14 2020-06-11 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2019122052A2 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
PH12021553042A1 (en) 2019-06-06 2023-09-11 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Cd8多肽、組合物及其使用方法
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス,アイエヌシー. 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
EP4661902A1 (en) * 2023-02-06 2025-12-17 Memorial Sloan-Kettering Cancer Center Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026006495A1 (en) * 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141271A1 (es) * 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
WO2015070078A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
US20140271644A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
JP6553069B2 (ja) * 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗wt1/hla二重特異性抗体
US20160152725A1 (en) * 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.

Similar Documents

Publication Publication Date Title
JP2018536393A5 (enExample)
JP2024038003A5 (enExample)
JP2017505125A5 (enExample)
JP2015535828A5 (enExample)
JP2014526898A5 (enExample)
JP2020536488A5 (enExample)
JP2020500538A5 (enExample)
JP2012143232A5 (enExample)
JP2019536806A5 (enExample)
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2013542194A5 (enExample)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2015514110A5 (enExample)
JP2018521638A5 (enExample)
JP2013538057A5 (enExample)
JP2012116856A5 (enExample)
JP2015503909A5 (enExample)
JP2021500916A5 (enExample)
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2017525343A5 (enExample)
JP2023093753A5 (enExample)
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения